IPO Databook: PrimeGenX Therapeutics (HK) - Jul 2026

108 Views26 Jul 2026 10:22

SUMMARY

PrimeGenX Therapeutics Co., Ltd. is a biotech company founded in 2016, specializing in locally-delivered targeted therapies for immune-inflammation diseases.
The pipeline includes 4 proprietary drug candidates and 5 generic drug candidates, with PG-011 targeting atopic dermatitis and allergic rhinitis.
Cash and cash equivalents were RMB127,682 thousand as of April 30, 2026, with net liabilities of RMB(7,191) thousand.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream